Mukka Proteins Ltd. (MUKKA) — Tipsheet

Mukka Proteins gets partial tax relief, ₹7.55 cr rate dispute remains

Tipsheet Editorial — Wed, 01 Jul 2026 17:13:47 GMT

Income Tax appellate order deletes ₹3.60 cr and ₹4.48 cr in additions but sustains ₹7.55 cr. The contested 78% vs 34.944% tax rate could determine the final hit.

What’s new

Tax appellate partly allows appeal, deleting ₹3.60 cr excess stock and ₹4.48 cr prior period income additions.
Sustains ₹7.55 cr addition for excess stock; company had already paid tax at 34.944%.
Dispute: whether the sustained amount is taxed at 78% special rate or normal rate; final impact depends on further steps.

Why it matters

The order removes some contingent liabilities but leaves a ₹7.55 cr exposure with a potential 78% tax rate. However, the incremental tax is modest relative to Mukka's ₹714 cr market cap, so the investment thesis remains intact.

What we’re watching

Whether the company appeals the sustained addition and the rate application.
Any adjustments to tax provisions in upcoming quarterly results.
Broader working capital cycle and credit rating, given prior CARE downgrade.

The full read

Mukka Proteins received a mixed tax appeal order for assessment year 2018-19. The Commissioner of Income Tax (Appeals) deleted additions of ₹3.60 crore for alleged excess stock and ₹4.48 crore for prior period income, but sustained ₹7.55 crore for excess stock. The dispute now centers on whether that ₹7.55 crore should be taxed at a punitive 78% under section 115BBE or the normal 34.944% the company already paid. The incremental tax, though uncertain, is modest relative to Mukka's ₹714 crore market cap and likely net worth. The company is evaluating its legal options. For now, the order removes some contingent liabilities but leaves a manageable uncertainty.

Primary source: BSE · NSE

Mukka Proteins raises ₹47 cr via warrants, buys two fish meal firms for ₹26 cr

Tipsheet Editorial — Fri, 12 Jun 2026 17:27:04 GMT

The micro-cap protein player is tackling liquidity stress flagged by a recent credit downgrade while expanding core production capacity via two acquisitions.

What’s new

Board approved preferential allotment of 2 cr warrants at ₹23.50 each to 15 non-promoter investors, raising ₹47 crore.
Board cleared acquisition of 51% in Delta Marine for ₹11.1 cr and 51% in Aqua Marine for ₹15 cr.
Delta Marine had a loss of ₹19.7 lakh on revenue of ₹28.2 cr in FY25; Aqua Marine posted ₹10.7 lakh profit on ₹32.2 cr revenue.

Why it matters

Mukka is under liquidity pressure after a recent credit downgrade. The ₹47 crore warrant issue (7.3% of market cap) directly addresses that, while the two fish meal acquisitions expand capacity in a core segment. But one target is loss-making, and dilution is 6.7%: the trade-off balances a clearer balance sheet against near-term EPS drag.

What we’re watching

Conversion of warrants: 18-month window; early conversion would strengthen equity.
Delta Marine turnaround timeline — at current losses it's a drag on margins.
Whether working capital cycle eases with the fresh equity infusion.

The full read

Mukka Proteins is raising ₹47 crore via a preferential warrant issue at ₹23.50 each to 15 non-promoter investors. That's 7.3% of its market cap, with 6.7% potential dilution. Separately, it is buying 51% of Delta Marine for ₹11.1 crore and 51% of Aqua Marine for ₹15 crore. Delta Marine lost ₹19.7 lakh on ₹28.2 crore revenue in FY25; Aqua Marine earned ₹10.7 lakh on ₹32.2 crore. A calculated bet. The capital raise directly addresses the liquidity stress that triggered a CARE downgrade in May. The warrant structure gives cash now and pushes dilution 18 months out. For a ₹682 crore company, this is a material shift, offering balance sheet relief against future dilution and the challenge of turning around a loss-making target.

Primary source: BSE · NSE

Mukka Proteins board to meet on June 12 for equity fundraise after credit downgrade

Tipsheet Editorial — Tue, 09 Jun 2026 17:26:28 GMT

The board will consider raising funds via a preferential issue, rights issue, or another mode. The move follows a CARE Ratings downgrade citing a 189-day working capital cycle.

What’s new

Mukka's board will meet June 12, 2026 to consider raising equity capital.
The company has not disclosed the size or specific instrument.
The meeting follows a CARE Ratings downgrade that cited a 189-day working capital cycle and 95% average bank limit utilisation.

Why it matters

An equity raise is the clearest signal yet that Mukka's credit deterioration is forcing a balance-sheet fix. The lack of specifics leaves the scale of dilution unknown, but the trigger is clear: the company's liquidity is stretched, and it needs outside capital.

What we’re watching

Whether the June 12 meeting produces a concrete size and instrument choice.
The dilution terms: a preferential issue concentrates ownership, a rights issue does not.
CARE's next review — a successful raise could stabilise the rating outlook.

The full read

Mukka Proteins will meet on June 12 to decide how to raise new equity capital. The board hasn't picked an instrument yet; a preferential issue, a rights issue, and other modes are all on the table. The trigger is straightforward. CARE Ratings recently downgraded Mukka, citing a 189-day working capital cycle and 95% average bank limit utilisation. The company's credit profile has deteriorated, and this is the first concrete step to fix it. What remains unclear is the scale. No amount has been disclosed, which means the market can't yet gauge the dilution or the relief. For a micro-cap, that gap between announcement and detail is where the risk sits.

Primary source: BSE · NSE

CARE Ratings cuts Mukka Proteins' credit rating on liquidity stress

Tipsheet Editorial — Tue, 26 May 2026 17:28:05 GMT

A ballooning working capital cycle and negative cash flow have forced a one-notch downgrade for the fish meal exporter.

What’s new

CARE Ratings downgraded long-term facilities to CARE BBB- and short-term to CARE A3.
Working capital cycle stretched to 189 days, with inventory holdings reaching 192 days.
Operating cash flow turned negative at ₹123 crore for the year.

Why it matters

The company is running on fumes, with bank limit utilization at 95%. A negative outlook from the rating agency suggests that the liquidity crunch is not a one-off event but a structural problem for the business.

What we’re watching

Whether the company can reduce inventory levels to free up cash.
Potential increases in borrowing costs following the downgrade.
Future updates on the company's ability to service its ₹495 crore in rated debt.

The full read

Mukka Proteins faces a liquidity squeeze. CARE Ratings downgraded the company's long-term bank facilities to CARE BBB- and short-term facilities to CARE A3, citing a working capital cycle that has stretched to 189 days. Inventory levels have bloated to 192 days, a buildup that drained cash and left the company with a negative operating cash flow of ₹123 crore for the year. With bank limit utilization averaging 95%, the company has almost no headroom. The rating agency maintained a Negative outlook, signaling that the pressure on debt coverage and liquidity is likely to persist. For a firm with ₹495 crore in rated debt, this downgrade is a warning that borrowing costs may rise just as the company's ability to generate cash is under the most strain. The market has yet to fully account for this deterioration.

Primary source: BSE · NSE